|1.||Russell, Philip K: 1 article (07/2007)|
|2.||Dibner, Mark D: 1 article (02/2007)|
|3.||Trull, Melanie C: 1 article (02/2007)|
|4.||du Laney, Tracey V: 1 article (02/2007)|
|5.||Towse, Adrian: 1 article (04/2005)|
|6.||Kettler, Hannah: 1 article (04/2005)|
|7.||Check, Erika: 1 article (05/2004)|
02/01/2007 - "Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development."
05/06/2004 - "BioShield defence programme set to fund anthrax vaccine."
07/15/2007 - "In exercising the procurement authorities under Project BioShield, HHS has launched acquisition programs to address each of the 4 threat agents, including Bacillus anthracis (anthrax), smallpox virus, botulinum toxins, and radiological/nuclear agents, originally deemed by the Department of Homeland Security to be threats to the US population sufficient to affect national security. "
|2.||Wounds and Injuries (Trauma)
07/01/1993 - "The SWI rate was really low (congruent to 2.3%) and a favorable role played by Bioshield cannot be excluded, both minimizing the skin lesions of the surgeon's hands and reducing wound contamination by exogenous flora."
07/01/1993 - "All of them were treated, before and after surgery, with a foam emulsion (Bioshield) considered, from a theoretical point of view, to be able decrease the bacterial contamination of the surgical wounds. "
04/01/2005 - "This paper looks at design issues for APPCs for drugs and vaccines for diseases of poverty drawing on experience and lessons from three case studies: the introduction of the meningitis C vaccine in the United Kingdom; the Orphan Drug Act (ODA) in the United States of America (US); and the newly legislated US Project BioShield for bioterrorist interventions. "
|2.||Botulinum Toxins (Botulinum Toxin)